Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d'Amati G. Fusco N, et al. Among authors: pastena m. Crit Rev Oncol Hematol. 2023 Oct;190:104103. doi: 10.1016/j.critrevonc.2023.104103. Epub 2023 Aug 16. Crit Rev Oncol Hematol. 2023. PMID: 37595344 Review.
Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002.
Diotaiuti S, De Summa S, Altieri R, Dantona C, Tommasi S, Di Gennaro M, Rubini G, Pastena MI, Argentiero A, Zito FA, Silvestris N, Paradiso AV. Diotaiuti S, et al. Among authors: pastena mi. Oncol Lett. 2020 Sep;20(3):2469-2476. doi: 10.3892/ol.2020.11793. Epub 2020 Jul 1. Oncol Lett. 2020. PMID: 32782565 Free PMC article.
A Clinical Decision Support System for Predicting Invasive Breast Cancer Recurrence: Preliminary Results.
Massafra R, Latorre A, Fanizzi A, Bellotti R, Didonna V, Giotta F, La Forgia D, Nardone A, Pastena M, Ressa CM, Rinaldi L, Russo AOM, Tamborra P, Tangaro S, Zito A, Lorusso V. Massafra R, et al. Among authors: pastena m. Front Oncol. 2021 Mar 11;11:576007. doi: 10.3389/fonc.2021.576007. eCollection 2021. Front Oncol. 2021. PMID: 33777733 Free PMC article.
Analyzing breast cancer invasive disease event classification through explainable artificial intelligence.
Massafra R, Fanizzi A, Amoroso N, Bove S, Comes MC, Pomarico D, Didonna V, Diotaiuti S, Galati L, Giotta F, La Forgia D, Latorre A, Lombardi A, Nardone A, Pastena MI, Ressa CM, Rinaldi L, Tamborra P, Zito A, Paradiso AV, Bellotti R, Lorusso V. Massafra R, et al. Front Med (Lausanne). 2023 Feb 2;10:1116354. doi: 10.3389/fmed.2023.1116354. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36817766 Free PMC article.
NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma.
Saponaro C, Vagheggini A, Scarpi E, Centonze M, Catacchio I, Popescu O, Pastena MI, Giotta F, Silvestris N, Mangia A. Saponaro C, et al. Among authors: pastena mi. J Exp Clin Cancer Res. 2018 May 2;37(1):96. doi: 10.1186/s13046-018-0766-7. J Exp Clin Cancer Res. 2018. PMID: 29716631 Free PMC article.
120 results